OncoMatch/Clinical Trials/NCT05259709
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
Is NCT05259709 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including 89Zr˗DFO˗REGN5054 and cemiplimab for advanced solid tumor.
Treatment: 89Zr˗DFO˗REGN5054 · cemiplimab — This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer. The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1 therapy
Prior treatment with a blocker of the PD-1/Programmed death ligand 1 (PD-L1) pathway
Cannot have received: CAR-T cell therapy
Currently receiving or has received chimeric antigen receptor (CAR-T) cell therapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify